Gilead Announces 48-Week Data From Two Pivotal Phase III StudiesEvaluating Viread(R) For The Treatment Of Chronic Hepatitis B

Gilead Sciences, Inc. (Nasdaq: GILD) announced the presentation of detailed 48-week data from two phase III pivotal clinical trials, Studies 102 and 103, which evaluate the safety and efficacy of once-daily Viread® (tenofovir disoproxil fumarate) among adult patients with chronic hepatitis B virus (HBV) infection. [click link for full article]

More: continued here

Filed under: Clinical Trials on November 6th, 2007